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As a recently appointed Topic Editor of Crystal Growth &Design, I am delighted to take the opportunity oﬀered by
this Perspective article to introduce myself to the journal’s
readers. Rather than subjecting you to a potted history of our
career milestones and achievements, my fellow Topic Editors
and myself will be using these articles to express our individual
views on subjects that lie at the heart of Crystal Growth &
Design, while describing some of the research being pursued in
our laboratories. With this in mind, it will be suﬃcient for now
to introduce myself as an organic solid-state chemist with a
passion for molecular crystals and a keen interest in crystal
engineering. I am privileged to lead a growing research group at
University College London, where we study (among other
things) supramolecular structures in molecular crystals, how
such crystals form, and how they can be put to good use.
This Perspective article was inspired in part by the many
discussions I have had with colleagues regarding our ability to
design molecular crystals for bespoke applications. The ﬁeld of
pharmaceutical solid-state chemistry is particularly successful in
demonstrating how crystal engineering and cocrystallization
can help to tackle the myriad challenges associated with
retaining promising molecules in drug discovery pipelines.1
This success can be easily credited to the tremendous
improvements (over the last 20 years) in our understanding
of molecular self-assembly in the solid state2−7 and of how
supramolecular interactions, such as hydrogen and halogen
bonds, steer such processes,8−14 as well as to the development
of sophisticated and reliable screening methods for polymorph,
salt, and cocrystal screening.15−17 These developments have
been accompanied by commensurate advances in analytical
tools for the characterization of molecular solids and dynamic
processes occurring therein (both in situ and ex situ).18 But
despite this great expansion in knowledge and expertise, organic
solids still baﬄe us more often than we would like, with sudden
unpredictable alterations that confound eﬀorts to regulate the
crystal form of a particular compound. The cases of ranitidine
hydrochloride, ritonavir, rotigotine, and other pharmaceuticals
have clearly demonstrated that there is much to learn before we
can claim full control over the organic solid state.19 As the title
of this article suggests, I believe that there are still substantial
hurdles to overcome before we can easily and precisely practice
the three main aspects of crystal engineering, namely, designing,
building, and using crystal structures.20
In the following sections, I will describe some of the hurdles
encountered by our research group when studying each of the
aforementioned aspects of crystal engineering. These examples
from our research should illustrate the “backbreaking” nature of
the crystal engineering endeavor, as well as the limitations of
our current abilities to understand, engineer, and maintain
molecular crystals; I leave it to the reader to imagine the
gratiﬁcation to be gained by overcoming these limitations in the
future.
■ DESIGNING CRYSTALS
My ﬁrst example concerns a recent study of cocrystal design,
involving cocrystals of theophylline (thp) and each of 19
diﬀerent ﬂuorobenzoic acids (FBA) (Figure 1a).21 The aim of
the study was to predict the formation of supramolecular
synthons in each of the 19 cocrystals. There were several
reasons to expect that the cocrystallization would proceed in a
straightforward manner: thp and benzoic acid (BA) are well
studied in the context of pharmaceutical cocrystals, while FBAs
are similar to BA in size, shape, and their capacity to engage in
hydrogen bonding. FBAs are also small, rigid molecules,
displaying a very limited number of potential hydrogen-
bonding functional groups. In addition, we could easily access
numerous well-established computational methods (e.g.,
predictions of molecular complementarity,22 ΔpKa calcula-
tions,23 and calculations of molecular electrostatic potential
surfaces24−27) and statistical tools (e.g., knowledge-based
hydrogen-bond propensity calculations28,29) to predict the
outcome of the proposed cocrystallizations.
However, initial database searches, quantum-chemical
calculations, and statistical analyses were not too helpful, as
two supramolecular interactions (labeled as A and B in Figure
1) were found to have a very similar propensity to occur in the
two-component cocrystal. Furthermore, neither a (thp)·(BA)
cocrystal nor cocrystals based on thp and a BA derivative
lacking additional hydrogen-bonding functional groups were
known at that time. This meant that we did not have suﬃcient
information to attempt reverse crystal engineering, i.e., the
extraction of design principles from similar/related crystal
structures (the latter process is often imprecisely described
simply as “engineering”). We were thus only able to
hypothesize that all di-, all tri-, and all tetra-substituted FBAs
might display identical synthons. It was also possible that
mono- and disubstituted FBAs would behave in a similar
manner, while tetra- and penta-substituted FBAs would act
similarly, though in another way.
The naivety of our hypotheses was exposed by the results of
the ensuing synthesis. All cocrystals were prepared under
identical mechanochemical conditions, but subsequent struc-
tural analysis showed that some FBAs formed a cocrystal, while
others did not. It was also interesting to note that crystallization
attempts carried out at two diﬀerent locations yielded
consistently diﬀerent synthon polymorphs30 (Figure 1b). In
addition, cocrystals containing FBAs with the same number of
ﬂuorine atoms exhibited diﬀerent compositions and supra-
molecular interactions. For example, thp and 25diFBA formed a
1:2 cocrystal, while 34diFBA and 35diFBA formed a 1:1 thp
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cocrystal, but the 34diFBA and 35diFBA cocrystals displayed
distinct supramolecular synthons (Figure 1c). The matter was
further complicated by the propensity of the (thp)·(FBA)
cocrystals to form polymorphsmany of which were synthon
polymorphs. A very limited polymorph screen showed that
synthetic conditions clearly dictate the formation of supra-
molecular synthons.
Given these observations, it would be complacent on our
part to be satisﬁed with our current ability to accurately predict
and understand the empirical outcomes of cocrystallization
experiments, even when small and rigid molecules are involved
(and despite our ambitions being limited to the prediction of
hydrogen-bonding patterns, rather than the entire crystal
structure).
■ BUILDING CRYSTALS
My second example demonstrates that building a thermody-
namically stable cocrystal structure can be anything but
straightforward, even if sophisticated cocrystallization methods
are employed. This example also highlights how gaps in our
knowledge of the nucleation process and crystal growth of
multicomponent crystals can constrain cocrystallization eﬀorts.
The noughties witnessed a surge in interest in pharmaceutical
cocrystals that led to the development of numerous rapid,
eﬃcient experimental screening methods.15,17,31−33 The success
of these new methods has been attributed to the fact that the
applied cocrystallization conditions maximize the potential for
cocrystal formation, supposing a thermodynamically feasible
cocrystal phase exists.31,34 One must keep in mind, though, that
a negative outcome of a cocrystal screen does not necessarily
mean that the target cannot materialize under the studied
condition due to thermodynamic constraints. Considering the
Figure 1. (a) Molecular structures of thp and FBA cocrystal formers; (b) (thp)·(2FBA) and (thp)·(2FBA)·(CH3NO2) cocrystals obtained in
diﬀerent laboratories under identical mechanochemical reaction conditions; (c) supramolecular assemblies in thp cocrystals of diﬂuorobenzoic acids
based on diﬀerent compositions and hydrogen-bonding patterns.
Figure 2. Synthesis of the elusive (caf)·(BA) cocrystal through heteronuclear seeding. Several (caf)·(FBA) cocrystals (highlighted in black) were
selected as heteronuclear seeds due to their structural similarity with the lowest-energy predicted (caf)·(BA) structure (highlighted in green). Powder
X-ray diﬀraction studies showed that the obtained (caf)·(BA) is indeed identical to the lowest-energy predicted cocrystal structure, as evidenced by
the overlay on the bottom right (red: predicted structure, blue: observed structure).
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established eﬀectiveness of contemporary cocrystallization
methods,35 however, it is not surprising that one is often
tempted to (injudiciously) ascribe a failed cocrystallization
attempt to the inability of the cocrystal formers to form stable
supramolecular structures and/or crystal lattices.
This was the case with the cocrystal based on caﬀeine (caf)
and benzoic acid (BA) with a 1:1 caf/BA ratio, a latent material
whose elusiveness was explained by the inability of its
components to form supramolecular structures capable of
packing into a thermodynamically stable crystal lattice.36 The
synthesis of the (caf)·(BA) cocrystal was unsuccessfully
attempted on numerous occasions in the last 60 years.36−38
After a series of unsuccessful attempts to prepare this cocrystal
in our laboratories, we turned to computational crystal
structure prediction and global lattice energy minimization
calculations to assess the possible existence of the target
material. Comparing the calculated energies of the pure
cocrystal components with the energy of the most stable
predicted cocrystal clearly indicated that the formation of (caf)·
(BA) is thermodynamically feasible. This result suggested that
the negative cocrystal screens might be due to unsuccessful
nucleation of the solid and that, perhaps, a high kinetic barrier
hinders the nucleation and growth of the thermodynamically
stable target cocrystal.
We then resorted to heteronuclear seeding experiments using
cocrystals composed of caf and FBAs. It was found that several
FBA isomers form caf cocrystals that are isomorphous with the
lowest energy (caf)·(BA) structure predicted. The synthesis of
such heteronuclear seeds and their subsequent use in our
cocrystallization experiments resulted in the formation of the
target solid. This success came at a cost: once the target solid
was obtained, we found that we were no longer able to
reproduce the initial negative screening results, which meant
that we were unable to explore the nonseeded system in further
detail. We then proceeded to repeat the full set of experiments
in four diﬀerent academic and industrial laboratories, with the
same outcome in each location: viz. initially, the target cocrystal
could not be prepared using well-established cocrystallization
methods, but formed immediately once a seed was introduced
to the laboratory. In all instances, the failed cocrystallization
experiments could not be reproduced for a signiﬁcant period
after the seeding experiments were performed (in some
laboratories, for more than two years!).
The inability to reproduce the failed experiments was
attributed to residual (and undetectable) crystals of either the
synthesized target cocrystal (or the heteronuclear seeds) in the
laboratory environment, which were presumably seeding19 the
formation of (caf)·(BA) in experiments that did not involve the
deliberate use of seeds. To test this hypothesis, we attempted
cocrystal screens using physical mixtures of caf and BA that
were isolated in rubber-septa-sealed vessels prior to the
introduction of the (caf)·(FBA) cocrystal seed to the
laboratory. Once a solution-mediated phase transformation
was initiated, the suspension did not convert within more than
3 days (as conﬁrmed by in situ Raman spectroscopy), but once
the septum was removed, the caf/BA mixture rapidly converted
into the cocrystal.
This intriguing instance of an elusive cocrystal process
responding in an irreversible fashion to heteronuclear seeding
suggests that contemporary screening methods need to be
further developed to avoid misleading false negative results,
which could easily jeopardize the production of medically and
commercially important materials.
■ USING CRYSTALS
My third exampleinvolving a study of the mechanical
properties of paracetamol (pca, also knowns as acetamino-
phen)not only highlights how very nonobvious properties of
organic solids are, but also emphasizes the role of particle
features, other than their crystal structure (e.g., size, size
distribution),39 in the shaping of the properties of a material.
Paracetamol is a highly popular analgesic and antipyretic, and
is the most prevalent active pharmaceutical ingredient in
medicines sold in the U.S., being present in more than 600
prescription medicines or products sold “over the counter”.40
The drug is a textbook example of a poorly tabletable molecule,
and the meager compaction properties of pca are generally
ascribed to its crystal chemistry. Two out of the three
polymorphs of pca are accessible with reasonable ease, the
monoclinic form I and the orthorhombic form II. The crystal
structure of pca-I exhibits two-dimensional corrugated hydro-
gen-bonded layers that impede plastic deformations of the pca
particles (Figure 3a) and contribute to the poor tabletability of
pca-I.41,42 The structure of pca-II, on the other hand, exhibits
ﬂat hydrogen-bonded molecular sheets, that facilitate plastic
deformation of the particles and thus better tabletability (Figure
3a).41,43 Unfortunately, pca-II is less stable than pca-I44,45 and is
Figure 3. (a) Crystal structure of pca-I and pca-II (viewed along the c and a crystallographic axes, respectively), (b) comparison of stress−density
curves for commercial pca-I (black) and sonocrystallized pca-I (red). The relative density (x-axis) refers to the powder density relative to the density
of the pca-I crystal structure (ρ = 1.263 g cm−3). Inset: tablets composed of commercial and sonocrystallized pca-I after compaction).
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also less accessible as a phase pure material. The formulation
scientist’s polymorph of choice is therefore pca-I, which is
formulated with a signiﬁcant amount of excipients to prevent
tablet failure in form of lamination, capping, and chipping,46
resulting in bulky tablets.
Pediatric patients, as well as some adults, generally suﬀer
from dysphagia (i.e., diﬃculty in swallowing). This means that
it is preferable to formulate medicines for this population in the
form of liquids, dispersible and chewable tablets.47 Accordingly,
numerous groups have attempted to improve the compaction
properties of pca through the development of alternative crystal
forms.48,49 It has also been demonstrated that microparticles of
pca-I, obtained using rather demanding crystallization methods,
exhibit improved compaction properties.47 Such material,
however, demands the use of compaction pressures that exceed
those deemed to be feasible in industrial settings.47
We have recently shown that fast and cost-eﬀective
sonocrystallization50 leads to the formation of phase-pure
pca-I, comprised of nano- and microcrystals, with signiﬁcantly
enhanced compaction properties.39 Compaction measurements
revealed that tablets of sonocrystallized pca-I exhibit 40% lower
porosity than those made from commercial, macrocrystalline
pca-I. Additional compaction simulations indicated that the
elastic modulus of the sonocrystallized pca-I particles expect-
edly increased51 (2.4-fold in comparison to commercial pca-I),
which should result in even worse compaction properties. The
excellent tabletability of the material, however, was enabled by
the improved ability of the solid to plastically deform, and a
substantial increase of the cohesion particles in the solid (34-
fold in comparison to commercial pca-I). As a result,
sonocrystallized pca-I displays compaction behavior that is
fairly close to that of microcrystalline cellulosea pharma-
ceutical excipient commonly used as binder to maintain the
structural integrity of tablets. Moreover, it was demonstrated
that sonocrystallized pca-I can be tableted using pressures that
are routinely used in industry without the addition of any
binders!
The surprising revelation that the tabletability of pca can be
improved to such remarkable extent by changing the size of the
crystals emphasizes the unpredictable behavior of molecular
crystalseven those of highly relevant and extensively studied
drug molecules. It also encourages the typical crystal engineer
to consider tackling formulation challenges via particle
engineering,52 viz. to improve material properties by tuning
particle size, size distribution, and morphology of the
compound of interest, rather than focusing solely on crystal
lattice adjustments.
The three examples described here may appear to oﬀer an
unduly critical picture of the current state of the art in the ﬁeld
of crystal engineering; however, that is certainly not my
intention. I believe that we are currently witnessing an era of
exciting advances in the ﬁeld,53 enabled by new and well-
developed experimental techniques, sophisticated instrumenta-
tion, and ingenious theoretical tools given force by powerful
computers. And this progress is, unsurprisingly, underpinned by
many studies that report targeted changes to crystal lattices of
specialty chemicals leading to their enhanced performance. But
in the midst of such sustained success, it is very important to be
mindful of the very real issues still facing practitioners.
Several of these issues were encountered in our work with
the (caf)·(BA) and (thp)·(FBA) cocrystals, which show that
our ability to target and control the formation of particular
supramolecular structures in cocrystals, or even to occasionally
materialize elusive or “disappearing” crystal forms (brieﬂy
discussed below54−59), leaves much to be desired. I am not
under the illusion that we will be able to fully plan and
successfully execute the construction of any imaginable crystal
lattice any time soon (or perhaps at all?)particularly not if
the ﬁeld continues to predominantly rely on crystallographic
studies, no matter how systematic and carefully conceived they
are. But I would prefer we refrain from exhausting ourselves
trying to attain such goal. Instead, we would perhaps be better
employed trying to master the mapping of crystal structure
landscapes, to understand which crystal structures are
experimentally obtainable, to reliably produce and maintain
them, and, ﬁnally, to predict what properties these materials
have, even before they were synthesized.60 Such an undertaking
is certainly very ambitious and perhaps too demanding for
many chemical crystallographers (which is what most of us in
the ﬁeld trained as). The experimentalists should, therefore,
join eﬀorts with theoretical solid-state chemists and physicists
whenever possible (a preferred mode of operation in our
research group39,61,62) and introduce computational methods
(e.g., lattice energy calculations,63 crystal structure predic-
tion64), knowledge-based predictive tools,65,66 and emerging
preparative and analytical techniques67,68 as standard tools into
their research programs. Until we do so, we will struggle to
uncover obscure (but potentially useful) qualities of existing
molecular materials, while continuing to engineer novel
molecular crystals with an incomplete understanding of the
principles underlying their structure and formation.
I recognize that such a move toward more multidisciplinary
and collaborative investigations of fundamental aspects of
crystal engineering would require a rather daunting rethink of
many research programs in the ﬁeld. I also realize that such
changes can only take place slowly, as it will take a while before
the expertise and tools of theoretical solid-state chemists
become more accessible to experimentalists, especially since
most relevant software is neither commercially available nor
facile to use. But I ﬁrmly believe that we are already on our way
to tackling many of these challenges, and I look forward to
seeing the positive impacts of such discipline-wide changes in
the near future. I hope that our endeavors to better control and
understand the solid state will not only beneﬁt the ﬁeld of
pharmaceutical formulations,69,70 but will also stimulate
solutions71 to many outstanding chemical problems,72 such as
materials for the storage and distribution of clean energy,73 and
uncovering the processes that enabled the origins of life.74
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